Culture Medium Contains A Growth Factor Or Growth Regulator Patents (Class 435/384)
  • Patent number: 10131877
    Abstract: Provided is a differentiation-inducing culture medium additive for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition, and a use of the differentiation-inducing culture medium additive. The differentiation-inducing culture medium additive of the present invention for inducing differentiation of a stem cell under a serum-free condition at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and ?-glycerophosphate. The differentiation-inducing culture medium additive of the present invention does not require ascorbic acid 2-phosphate and ITS, which are normally essential for bone differentiation. Further, bone differentiation can be promoted by adding phospholipid.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: November 20, 2018
    Assignee: TWO CELLS Co., Ltd.
    Inventors: Yukio Kato, Jin Chang Shao, Koichiro Tsuji
  • Patent number: 9969971
    Abstract: The present invention generally relates to calcium-containing structures and methods of making and using the structures. In one aspect, hollow calcium containing microstructures are used in conjunction with bone tissues/by-products to augment bone defects and extend the supply of bone tissues/by-products for bone augmentation. Bonding agents, such as calcium cements, are also used in the preparation of the hollow calcium microstructures combined with bone tissues/by-products or for use in preparing the hollow microstructures. The calcium-containing microstructures of the present invention are also useful as delivery vehicles of nitric oxide and/or nitric oxide containing or producing compounds for a variety of in vitro and in vivo uses. Calcium containing contoured substrates upon which cells/tissues can be grown in vitro for replacement and repair of tissues in vivo that conform in size and shape to the tissue surface to be replaced are also provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: May 15, 2018
    Assignee: CAP Biotechnology, Inc.
    Inventors: L. Brian Starling, James E. Stephan
  • Patent number: 9879226
    Abstract: Disclosed is a basic culture medium for mesenchymal stem cells, and a cell therapeutic agent cultured and differentiated using same. The basic culture medium reduces the time taken from collection to mass culturing by increasing the proliferation rate of undifferentiated mesenchymal stem cells derived from an adult tissue such as human marrow and adipose tissue, and also is capable of various differentiations into treating agents for bone-forming cells, for cartilage cells, or for fat cells.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: January 30, 2018
    Assignee: SEWON CELLONTECH CO., LTD.
    Inventors: Dong-Sam Suh, Jun Keun Lee, Dong Il Chang, Min Jung Choi, Jang Hoon Kim, Ga Ram Kim, Cheong Ho Chang
  • Patent number: 9868935
    Abstract: The present disclosure describes a method and composition for enhancing the survival of hematopoietic stem cells, preferably CD34+ derived from human umbilical cord or peripheral blood, in hypoxic and serum-deprived conditions by cultivating the cells in medium containing lysophosphatidic acid, preferably further comprising a gel, namely a biomimetic gel. The method and composition may be used in medicine or cosmetic application, in particular, in treatment of cardiac tissue and/or cardiac diseases, and/or in the treatment of wound healing namely diabetic wound healing.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 16, 2018
    Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.
    Inventors: Lino Da Silva Ferreira, Isabel Maria Fidalgo Dos Santos Silva Carvalho
  • Patent number: 9469672
    Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: October 18, 2016
    Assignee: Wyeth LLC
    Inventors: Shujun Sun, Christopher Gallo, Brian Kelley
  • Patent number: 9186379
    Abstract: The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: November 17, 2015
    Assignee: STEMNION, INC.
    Inventor: David L Steed
  • Patent number: 9061054
    Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: June 23, 2015
    Assignee: The Curators of The University of Missouri
    Inventors: Thomas P. Quinn, Natalia G. Karasseva
  • Patent number: 9040296
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: May 26, 2015
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Patent number: 9040299
    Abstract: The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 26, 2015
    Assignee: CELLRESEARCH CORPORATION PTE LTD
    Inventor: Toan-Thang Phan
  • Patent number: 9034647
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 19, 2015
    Assignee: CORMATRIX CARDIOVASCULAR, INC.
    Inventor: Robert G Matheny
  • Patent number: 9029145
    Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 12, 2015
    Assignee: The University Court of the University of Edinburgh
    Inventors: Brendon Stewart Noble, David Matthew Pier
  • Patent number: 9005967
    Abstract: The present invention provides a method for improving iPS cell generation efficiency, which comprises a step of introducing a Myc variant having the following features: (1) having an activity to improve iPS cell generation efficiency which is comparative to, or greater than that of c-Myc; and (2) having a transformation activity which is lower than that of c-Myc; or a nucleic acid encoding the variant, in a nuclear reprogramming step. Also, the present invention provides a method for preparing iPS cells, which comprises a step of introducing the above Myc variant or a nucleic acid encoding the variant and a combination of nuclear reprogramming factors into somatic cells. Moreover, the present invention provides iPS cells comprising the nucleic acid encoding the Myc variant which can be obtained by the above method, and a method for preparing somatic cells which comprises inducing differentiation of the iPS cells.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 14, 2015
    Assignee: Kyoto University
    Inventors: Shinya Yamanaka, Masato Nakagawa
  • Patent number: 8992906
    Abstract: Embodiments herein relate to compositions and methods for engraftment of and increasing survival of muscle cells in a subject in need thereof. In certain embodiments, compositions including myofibers and/or satellite stem cells may be administered to a subject. Other embodiments relate to compositions and methods for introducing one or more compounds to a subject using cell compositions disclosed herein. Still other embodiments relate to uses of these compositions in kits for portable applications and methods.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Bradley Bruce Olwin, John K. Hall, Kathleen Kelly Tanaka
  • Publication number: 20150079659
    Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
    Type: Application
    Filed: May 22, 2014
    Publication date: March 19, 2015
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Stephen GORFIEN, Richard FIKE, GLENN GODWIN, JOYCE WOLANSKE, David EPSTEIN, Dale GRUBER, Don MCCLURE, Paul PRICE
  • Patent number: 8980628
    Abstract: This invention relates to methods of producing hair folliclesin vitro, compositions for producing hair follicles in vitro, in vitro produced hair follicles, methods of providing an in vitro produced hair shaft at an interfollicular or intrafollicular site, methods of treating hair loss by providing an in vitro produced hair shaft at an interfollicular or intrafollicular site and assays for studying the effect of test agents on hair biology. The invention also provides the similar methods and products which are, or use, immature follicles (“defined herein as proto-hairs”). The invention provides a method for in vitro production of a hair follicle or a proto-hair comprising co-culturing dermal papilla cells with keratinocytes, and optionally with melanocytes.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: March 17, 2015
    Assignee: Aderans Research Institute, Inc.
    Inventors: Jizeng Qiao, Jeffrey Keeler Teumer, Erica Jean Philips
  • Patent number: 8975072
    Abstract: Provided are: a method for producing an immortalized human erythroid progenitor cell line, enabling efficient and stable production of enucleated red blood cells; and a method for producing human enucleated red blood cells from a human erythroid progenitor cell line obtained by the aforementioned production method. An expression cassette capable of inducing expression of HPV-E6/E7 genes in the presence of DOX was introduced into the genomic DNA of blood stem cells. Then, the blood stem cells were cultured in the presence of DOX and a blood growth factor. Thereby, immortalized cell lines of human erythroid progenitor cells were established. Further, it was revealed that culturing the cell lines under a condition where the expression of the HPV-E6/E7 genes was not induced enabled differentiation induction into enucleated red blood cells at a high ratio.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 10, 2015
    Assignee: Riken
    Inventors: Yukio Nakamura, Ryo Kurita
  • Patent number: 8969081
    Abstract: Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: March 3, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Hynek Wichterle, Thomas M. Jessell, Mirza Peljto
  • Patent number: 8962324
    Abstract: A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component and a bioactive agent component. In a preferred embodiment, the ECM scaffold component comprises mesothelial tissue and the bioactive agent comprises a statin.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: February 24, 2015
    Inventor: Robert G Matheny
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 8956868
    Abstract: The present invention provides a method for producing iPS cells, comprising reacting cells with at least one connexin inhibitor and at least one TGF? signaling inhibitor; iPS cells comprising at least one connexin inhibitor; an iPS cell inducer comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; a medium for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; and a kit for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: February 17, 2015
    Assignee: LSIP, LLC
    Inventors: Tetsuro Takamatsu, Ping Dai
  • Patent number: 8956866
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Grant
    Filed: April 27, 2008
    Date of Patent: February 17, 2015
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
  • Patent number: 8951798
    Abstract: Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt/?-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt/?-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 10, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sean Palecek, Timothy Kamp, Xiaojun Lian
  • Patent number: 8951796
    Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 10, 2015
    Assignee: University of Southern California
    Inventors: Song Guo Zheng, David A. Horwitz, Juhua Wong
  • Patent number: 8951800
    Abstract: This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: February 10, 2015
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Ramkumar Mandalam, Chunhui Xu, Joseph D. Gold, Melissa K. Carpenter
  • Patent number: 8945922
    Abstract: Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the ?-chain region of the T cell antigen receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: February 3, 2015
    Assignee: Riken
    Inventors: Hiroshi Watarai, Haruhiko Koseki, Masaru Taniguchi, Shin-ichiro Fujii
  • Patent number: 8940535
    Abstract: Methods and compositions are provided for isolation of proliferating cells. In particular, the methods enrich stem cells in a mixture of stem cells and non-stem cells, and in some cases the non-stem cells may be differentiated cells. The methods exploit the non-adherent property of stem cells, as opposed to the adherent property of differentiating cells, by serially passaging the suspended cells in liquid media.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: January 27, 2015
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Dept of Veterans Affairs
    Inventors: G. David Trisler, Christopher T. Bever, Jr., James E. Goolsby, Bernard M. Pessac
  • Patent number: 8940537
    Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: January 27, 2015
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Debora Steiner
  • Publication number: 20150024491
    Abstract: An object of the present invention is to develop and provide a method for producing a neuron model having reproduced in vivo properties by improving a cell culture medium composition and a cell culture medium composition necessary for the production of such neuron model. According to the present invention, cell culture is carried out in vitro using a medium for producing in vivo-like and enhanced synaptogenesis neuron model supplemented with a medium supplement for producing in vivo-like and enhanced synaptogenesis neuron model comprising any or any combination of NT-3, potassium or a salt thereof, and FGF2.
    Type: Application
    Filed: March 27, 2012
    Publication date: January 22, 2015
    Applicant: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY
    Inventors: Dimitar Ivanov Dimitrov, Laurent Elie Guillaud, Zacharie Mehdi Francois Taoufiq, Tomoyuki Takahashi
  • Patent number: 8936939
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: January 20, 2015
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Publication number: 20150017134
    Abstract: In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 15, 2015
    Inventors: Wenjun Guo, Robert A. Weinberg, Zuzana Keckesova
  • Patent number: 8927281
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: January 6, 2015
    Assignees: IRM LLC, The Scripps Research Institute
    Inventors: Anthony E. Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Tellew, Yongqin Wan, Xing Wang
  • Patent number: 8927276
    Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: January 6, 2015
    Assignee: Cellin Technologies OUE
    Inventors: Kaia Palm, Toomas Neuman
  • Publication number: 20150004146
    Abstract: Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.
    Type: Application
    Filed: February 13, 2012
    Publication date: January 1, 2015
    Applicant: Gamida-Cell Ltd.
    Inventors: Tony Peled, Yair Steinhardt
  • Patent number: 8895299
    Abstract: A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: November 25, 2014
    Assignee: XON Cells, Inc.
    Inventor: Neil H. Riordan
  • Patent number: 8895303
    Abstract: In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 25, 2014
    Assignee: Charite-Universitatsmedizin Berlin
    Inventors: Josef Priller, Christel Bonnas, Andreas Meisel
  • Patent number: 8895300
    Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: November 25, 2014
    Assignee: Viacyte, Inc.
    Inventor: Thomas C Schulz
  • Patent number: 8895301
    Abstract: A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: November 25, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xiaoqing Zhang
  • Publication number: 20140335616
    Abstract: The present invention provides cell culture media formulations which support the in vitro cultivation of animal epithelial cells. The media comprise at least one fibroblast growth factor (FGF) and at least one agent that induces increased intracellular cAMP levels, and optionally comprise ascorbic acid. The present invention also provides methods of cultivating animal epithelial cells in vitro using these cell culture media formulations, kits comprising the media, cell culture compositions comprising the culture media and an animal epithelial cell, and compositions that may be used as replacements for organ or gland extracts in animal cell culture media.
    Type: Application
    Filed: August 14, 2013
    Publication date: November 13, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David JUDD, Paul Battista
  • Patent number: 8883504
    Abstract: The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and a cell prepared by culturing using this differentiation inhibiting agent. The present invention provides a differentiation inhibiting agent which comprises a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient; a method for safely culturing a stem cell in large scale in undifferentiated state in the absence of feeder cell which comprises culturing a stem cell by using a tetrahydroisoquinoline derivative; a culture liquid for stem cells comprising a tetrahydroisoquinoline derivative; and a cell which is obtained by culture using a tetrahydroisoquinoline derivative as a differentiation inhibiting agent.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 11, 2014
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Tomoyuki Miyabayashi, Masashi Yamamoto
  • Patent number: 8883502
    Abstract: The invention provides methods for obtaining neural stem cells from a mammalian embryonic or inducible pluripotent stem cell population comprising culturing mammalian embryonic or inducible pluripotent stem cells in a cell culture medium having a leukemia inhibitory factor (LIF), an inhibitor of glycogen synthase kinase 3 (GSK3), and an inhibitor of transforming growth factor ? (TGF-?) under suitable conditions and obtaining isolated neural stem cells therefrom.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: November 11, 2014
    Assignee: The Regents of the University of California
    Inventors: Kang Zhang, Sheng Ding
  • Patent number: 8871511
    Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: October 28, 2014
    Assignee: CorMatrix Cardiovascular, Inc
    Inventors: Robert G Matheny, Anna Fallon
  • Patent number: 8871510
    Abstract: This disclosure describes methods for differentiating T cells and NK cells in vitro from hematopoietic stem cells or precursor cells. The technology is directed to methods for the production of selected populations of lymphocytes, such as T cells and NK cells. The availability of such cell populations allows for the complete reconstitution of a depleted, defective or missing lymphocyte population in a patient.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 28, 2014
    Assignee: University of Utah Research Foundation
    Inventors: Gerald John Spangrude, Birgitta H. Mitchell, Jared Manning
  • Patent number: 8859280
    Abstract: A composition and method for in vitro fertilization is provided which uses culture media comprising elevated concentrations of lipoic acid. More specifically, the invention provides culture media for developmental cells having a lipoic acid concentration of 5 ?M to 40 ?M. Culture media that include lipoic acid at concentrations within the identified range are able to provide blastocysts with increased survival, increased cell numbers, increased inner cell masses and/or increased percentage of the total mass made up by the inner cell compared to blastocysts cultured in a control medium.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: October 14, 2014
    Assignee: Vitrolife Sweden AB
    Inventors: David K Gardner, Mark G Larman, Donald Linck
  • Publication number: 20140295552
    Abstract: The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation. Specifically, the invention discloses methods of differentiating pluripotent cells into beta cell, cardiac cell and neuronal cell lineages using suspension clustering. The methods involve preparing the aggregated cell clusters followed by differentiation of these clusters.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Benjamin FRYER, Daina Laniauskas, Marcia Blackmoore, Haiyun Wang, Kostadinka Lilova, Shelley Nelson, Elizabeth Rosocha
  • Patent number: 8841123
    Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 23, 2014
    Assignee: Regenerative Research Foundation
    Inventors: Jeffrey Stern, Sally Temple Stern
  • Patent number: 8815597
    Abstract: The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: August 26, 2014
    Assignee: Takara Bio Inc.
    Inventors: Hideto Chono, Junichi Mineno, Kazutoh Takesako, Takao Yoshida, Takashi Morimura, Kenji Sakai, Shin-ichi Yamada, Noritsugu Yabe, Yuko Taguchi
  • Patent number: 8802436
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: August 12, 2014
    Assignee: ACell, Inc.
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Patent number: 8802434
    Abstract: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: August 12, 2014
    Assignee: The University of Birmingham
    Inventor: Christopher Martin Bunce
  • Patent number: 8795530
    Abstract: The present invention relates to methods and systems for optimization of dilution of a viscous starting material to isolate and/or concentrate the product of interest from the starting source material such that the process minimizes the volume of diluent and the total volume of the waste stream generated during the process as well as maximizing the yield of desired product. The system employs cross-flow filtration modules with sub-channels that are equidistant to the inlet and outlet of said modules and such modules are characterized by optimal channel height, optimal transmembrane pressure, etc., which are selected in order to achieve the best combination of product quality and production yield.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: August 5, 2014
    Assignee: Smartflow Technologies, Inc.
    Inventors: Henry B. Kopf, James A. Kacmar
  • Patent number: 8785197
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 22, 2014
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny